Funding, News and Announcements

This competitive program seeks to support global research that helps to address Ulcerative Colitis data gaps and advances the understanding of etrasimod and / or tofacitinib role in the treatment landscape.

Potential applicants are encouraged to identify and address the data gaps and advances understanding the role of etrasimod and tofacitinib in UC treatment landscape. This may include

• Exploration for optimal ultrasonographic markers
• Evaluation of UC extraintestinal manifestations
• Evaluation in specific subgroups of special interest
• Evaluation of advanced therapy sequencing strategy

Funding Range and Project Length: Individual projects requesting up to USD 200,000 will be considered. The project length will be a maximum of eighteen (18) months.

Full details are available here.

Contact Details

Internal: ird@dal.ca
External: Amanda Stein (amanda.j.stein@pfizer.com) with the subject line “Research in Ulcerative Colitis (UC) 2024.”

Deadlines

Internal: July 22, 2024
External: August 5, 2024

The grants facilitator for your faculty can be found on the staff contact page. For additional resources, click here for guidance on internal deadlines and submission processes.